Wegovy Dosage Chart & Titration Schedule.

Check how far away your next scheduled dose is. More than 2 days away: inject the missed dose as soon as you remember, then carry on with your normal day. Less than 2 days away: skip it entirely and take your next dose on schedule; never double up to catch up. The one situation that changes the plan is missing 2 or more consecutive weeks: the label then says to restart at a lower dose and re-escalate, because gut tolerance fades quickly and jumping straight back to your previous dose is a reliable way to end up vomiting.

No, and the reason is worth understanding. The ladder is not a potency issue, it is a tolerability schedule; the low doses exist purely so your gut can adapt. Semaglutide’s ~1-week half-life means blood levels take roughly 4 – 5 weeks to plateau after any change, so a 4-week step is the minimum time needed to know whether you actually tolerate that level. Compressing the schedule does not speed up weight loss; it produces nausea, vomiting, dehydration and dropouts. The label only ever moves in the other direction: if a step is rough, hold it for 4 extra weeks.

Same molecule, different products. Both are semaglutide from the same manufacturer, but they are approved for different things at different doses in different devices. Ozempic is indicated for type 2 diabetes and tops out at 2 mg weekly in a multi-dose dial pen. Wegovy is indicated for weight reduction, cardiovascular risk reduction and MASH, and goes to 2.4 mg (or 7.2 mg on the high-dose pen), mostly in fixed single-dose pens you cannot dial. They are not interchangeable prescriptions, and taking both, or either alongside another GLP-1, is explicitly not recommended.

For most people, no. The FDA approved 7.2 mg (Wegovy HD) in 2026 for adults on the weight-reduction indication who have tolerated 2.4 mg for at least 4 weeks and still need more weight loss. The trade is unattractive for the average user: STEP UP showed about 3.3 extra percentage points of weight loss (−18.8% vs −15.5% at 72 weeks) in exchange for dysesthesia rising from 6% to 22%. Among people who developed dysesthesia at 7.2 mg and then re-escalated after recovering, 45% had it come back. It is not approved for cardiovascular risk reduction, MASH, or under-18s.

1.7 mg is a fully labelled maintenance dose, not a consolation prize. The FDA label names either 1.7 mg or 2.4 mg as maintenance for weight reduction and cardiovascular risk reduction, with 2.4 mg recommended, and tells prescribers to choose based on both response and tolerability. If you are losing weight well at 1.7 mg with manageable side effects, there is no clinical requirement to climb further. What is not a maintenance option is parking at 0.25, 0.5 or 1 mg; those rungs are escalation-only and were never studied as endpoints.

Yes, and the label gives exact timing. Pen to pill: one week after your last 2.4 mg injection, start 25 mg tablets once daily. Pill to pen: the day after your last tablet, start 2.4 mg injection weekly, or 1.7 mg if you struggled with the 25 mg tablet. One caveat: oral semaglutide absorption is more variable, and in people with type 2 diabetes it runs lower than the injection, so the label warns some diabetic patients on tablets may sit at sub-therapeutic levels and should consider switching to the pen if response is poor.

Not much, which is unusual for an injectable. The label confirms similar exposure whether you inject into the abdomen, thigh or upper arm, and allows any time of day, with or without meals. Rotate sites between doses. You can also change which day of the week you inject without any dose adjustment, provided at least 2 days separate consecutive doses, useful if your routine shifts. The one thing that does matter is consistency: pick a day you will genuinely remember.

A Wegovy pen is a fixed, factory-filled dose with a known concentration; there is nothing to reconstitute and no syringe units to calculate, which removes the single largest source of dosing error. Compounded or grey-market semaglutide sold in vials shifts all of that onto you: concentration, reconstitution volume, draw accuracy, sterility and actual peptide content are unverified, and dosing errors on this drug are not quickly reversible given the 5 – 7 week clearance window. Numbers quoted on vendor sites frequently do not trace back to the FDA label. If you are using anything other than a licensed pen, the titration schedule on this page is still the schedule, but verify every calculation against the label, not a vendor’s chart.